Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration (“FDA”) approval in July 2023. Demodex blepharitis is caused by the infestation of Demodex mites.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Business segments
Q3 2023 · $418.0KThe company’s own SEC segment disclosure.
- License And Collaboration$218.0K52%
- License And Collaboration Other$200.0K48%
Tarsus Pharmaceuticals, Inc. (TARS) reported revenue of $174M in Q2 2026 (quarter ended June 30, 2026), up 69% from the same quarter a year earlier. That came with a gross margin of 93% and net loss of $19M. For the full year FY2025, revenue was $451M (+147% year on year) and net income −$66M. Its largest product in 2023-Q3 was License And Collaboration at $218K, 52% of the disclosed total, just ahead of License And Collaboration Other at 48%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.